Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note published on Friday. The brokerage issued a hold rating on the medical research company’s stock.

Several other equities research analysts also recently weighed in on the stock. HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Monday, January 13th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

Shares of CTSO opened at $1.30 on Friday. The company has a market cap of $71.08 million, a price-to-earnings ratio of -3.61 and a beta of 0.61. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company has a 50 day moving average of $0.98 and a two-hundred day moving average of $1.04.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its holdings in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after buying an additional 8,400 shares in the last quarter. Northern Trust Corp increased its stake in shares of Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after purchasing an additional 16,701 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Cytosorbents during the fourth quarter worth about $99,000. Geode Capital Management LLC increased its stake in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Sargent Investment Group LLC increased its stake in shares of Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after purchasing an additional 192,747 shares in the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.